celecoxib has been researched along with Anemia in 10 studies
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic inflammation is one of the main symptoms of cancer cachexia, and cyclooxygenase 2 inhibitors, such as celecoxib, may be beneficial in counteracting the major symptoms of this syndrome." | 3.81 | Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor. ( Bi, Y; Han, M; Jiang, M; Xu, X; Zhang, Y, 2015) |
| "The aim of this study was to predict the cost effectiveness of celecoxib, a cyclo-oxygenase 2 (COX-2) specific inhibitor, in the treatment of arthritis patients in Switzerland." | 3.71 | Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. ( Chancellor, JV; de Cruz, E; Hunsche, E; Sarasin, FP, 2001) |
| "Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
| "Treatment of celecoxib with a proton pump inhibitor is safer than treatment with nonselective NSAID and a proton pump inhibitor in high risk gastrointestinal and cardiovascular patients who mostly also take acetylsalicylic acid." | 2.52 | [Gastrointestinal bleeding]. ( Lanas, Á, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Shen, P | 1 |
| Zhang, XC | 1 |
| Zhao, MD | 1 |
| Zhang, XG | 1 |
| Yang, L | 1 |
| Xu, X | 1 |
| Jiang, M | 1 |
| Zhang, Y | 1 |
| Bi, Y | 1 |
| Han, M | 1 |
| Macciò, A | 1 |
| Gramignano, G | 1 |
| Madeddu, C | 1 |
| Lanas, Á | 2 |
| Goldstein, JL | 2 |
| Chan, FK | 1 |
| Wilcox, CM | 1 |
| Peura, D | 1 |
| Sands, GH | 1 |
| Berger, MF | 1 |
| Nguyen, H | 1 |
| Scheiman, JM | 1 |
| Montano-Pedroso, JC | 1 |
| Garcia, EB | 1 |
| Omonte, IR | 1 |
| Rocha, MG | 1 |
| Ferreira, LM | 1 |
| Krzyzanowska, MK | 1 |
| Tannock, IF | 1 |
| Lockwood, G | 1 |
| Knox, J | 1 |
| Moore, M | 1 |
| Bjarnason, GA | 1 |
| Gaffney, DK | 1 |
| Winter, K | 1 |
| Dicker, AP | 1 |
| Miller, B | 1 |
| Eifel, PJ | 1 |
| Ryu, J | 1 |
| Avizonis, V | 1 |
| Fromm, M | 1 |
| Greven, K | 1 |
| Burke, TA | 1 |
| Zabinski, RA | 1 |
| Pettitt, D | 1 |
| Maniadakis, N | 1 |
| Maurath, CJ | 1 |
| Chancellor, JV | 1 |
| Hunsche, E | 1 |
| de Cruz, E | 1 |
| Sarasin, FP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Scarpa´s Fascia in the Formation of Seroma Post Abdominoplasty After Bariatric Surgery[NCT01942707] | 46 participants (Actual) | Interventional | 2013-03-31 | Active, not recruiting | |||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of days required for drain withdrawal. The measure of drainage will be done at the same time (8:00 am) and by the same nurse everyday in all patients until the drain is withdrawn. The drain will be withdrawn when the drained volume is less than 30 ml in 24 hours. (NCT01942707)
Timeframe: Number of days required for drain withdrawal (drained volume less than 30 ml in 24 hours) and no later than 10 days
| Intervention | days (Mean) |
|---|---|
| Without Scarpa's Fascia | 5.4 |
| With Scarpa's Fascia | 4.2 |
We will measure the total volume of drainage, in ml, obtained by the drains in the abdominal region. The measure of drainage will be done at the same time (8:00 am) and by the same nurse everyday in all patients until the drain is withdrawn. The drain will be withdrawn when the drained volume is less than 30 ml in 24 hours. Total volume of drainage will be calculated as the sum of the volumes obtained daily. (NCT01942707)
Timeframe: number of days required for drain withdrawal (drained volume less than 30 ml in 24 hours) and no later than 10 days
| Intervention | ml (Mean) |
|---|---|
| Without Scarpa's Fascia | 428.9 |
| With Scarpa's Fascia | 249.1 |
An ultrasound of the abdominal wall will be realized to check the volume of any residual seroma. (NCT01942707)
Timeframe: Done after 20 days of surgery
| Intervention | ml (Mean) |
|---|---|
| Without Scarpa's Fascia | 21.6 |
| With Scarpa's Fascia | 16.8 |
3 reviews available for celecoxib and Anemia
| Article | Year |
|---|---|
Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cardiovascul | 2014 |
[Gastrointestinal bleeding].
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Blood Transfusion; Celecox | 2015 |
A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Clinical T | 2001 |
4 trials available for celecoxib and Anemia
| Article | Year |
|---|---|
Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
Topics: Adult; Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celeco | 2011 |
Hematological variables and iron status in abdominoplasty after bariatric surgery.
Topics: Abdominoplasty; Adult; Analgesics; Anemia; Anti-Bacterial Agents; Biomarkers; Celecoxib; Cyclooxygen | 2013 |
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.
Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2007 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |
3 other studies available for celecoxib and Anemia
| Article | Year |
|---|---|
Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor.
Topics: Anemia; Animals; Antibodies, Monoclonal; Body Weight; Cachexia; Celecoxib; Cell Line, Tumor; Cycloox | 2015 |
Surprising results of a supportive integrated therapy in myelofibrosis.
Topics: Anemia; C-Reactive Protein; Cachexia; Carnitine; Celecoxib; Curcumin; Erythropoietin; Fatigue; Ferri | 2015 |
Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Clinical T | 2001 |